Haematology trials spark safety concerns

The TGA has issued a warning of a “risk of serious adverse events” for some patients taking part in cancer trials of Gilead Sciences’ idelalisib (Zydelig).

The TGA says it is investigating “a significant safety concern involving idelalisib 100mg and 150mg tablets.”

Gilead alerted regulatory authorities because of adverse events, “mostly due to infections”, in